• Mashup Score: 0
    Tarlie ASCO talk.MP4 - 2 year(s) ago

    Tweet Tweets with this article
    • "Facing death head on has left me feeling calmer and more prepared for whatever comes." Grateful to @spruhajoshi_ who uploaded the video from Dr @TarlieTownsend's #ASCOQLTY21 talk on decision making for those who are critically ill. 🖤🖤🖤 📽️: https://t.co/29R15Kksf1

  • Mashup Score: 0

    With the ASCO Quality Care Symposium’s (QCS) hybrid annual meeting this year, we had the opportunity to offer both an in-person meeting format and virtual participation to the many members of our community who needed to attend remotely because of the ongoing COVID-19 pandemic. Oral speakers presented either onstage or remotely in real time to an audience listening in Boston and around the world….

    Tweet Tweets with this article
    • #JCOOP Editorial: "We challenge researchers at @ASCO to continue to promote trainees & provide them opportunities to be 1st authors & to present at national meetings, as was done at #ASCOQLTY21." Of 22 orals, ~60% were presented by trainees. 👉 https://t.co/reMAgNh4W2 @GRocqueMD https://t.co/RWKOjKqs6l

  • Mashup Score: 2

    The most powerful, simple and trusted way to gather experience data. Start your journey to experience management and try a free account today.

    Tweet Tweets with this article
    • Calling virtual/in person/or NON attendees of #ASCOQLTY21! Tell us about how you did after the meeting, so we can assess #covid infections and social mixing at oncology conferences https://t.co/skG09GF7ph @ASCO @ASCOPost fyi #radonc astro survey coming late november!

  • Mashup Score: 9

    New data on women with early breast cancer, presented during the 2021 ASCO Quality Care Symposium, suggest patients who are not well-represented in clinical trials may face reduced odds of survival, calling into question the generalizability of clinical trial results to real-world patients (Abstract 75).

    Tweet Tweets with this article
    • #ASCOQLTY21 data on women w early #breastcancer suggest pts who aren't well-repd in #clinicaltrials may face ⬇️ survival odds, calling into ❓ generalizability of trial results to real-world pts. https://t.co/DE0tLxQg7b #ASCODailyNews @GRocqueMD @OncoAlert @ASCO_pubs #JCOOP #bcsm